FDA slaps down Bristol-Myers’ marketing pitch for hep C drug daclatasvir

John Carroll

The FDA has slapped Bristol-Myers Squibb's closely watched hep C , handing out a complete response letter for the linchpin drug in its cocktail strategy.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS